First Time Loading...

AstraZeneca PLC
LSE:AZN

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
LSE:AZN
Watchlist
Price: 12 026 GBX 5.94% Market Closed
Updated: Apr 26, 2024
Section:
 

Relative Value

The Relative Value of one AZN stock under the Base Case scenario is 17 112.49 GBX. Compared to the current market price of 12 026 GBX, AstraZeneca PLC is Undervalued by 30%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AZN Relative Value
Base Case
17 112.49 GBX
Undervaluation 30%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5.1
P/S
P/S
Price to Sales
5.1
vs History
11
vs Industry
25
Median 3Y
4.6
Median 5Y
4.6
Industry
2.3
Forward
0
More Details
39
P/E
P/E
Price to Earnings
39
vs History
55
vs Industry
11
Median 3Y
37.3
Median 5Y
44.7
Industry
22.2
Forward
0.2
More Details
22.5
P/OCF
P/OCF
Price to OCF
22.5
vs History
66
vs Industry
21
Median 3Y
21.9
Median 5Y
25.4
Industry
16.7
More Details
52.8
P/FCFE
P/FCFE
Price to FCFE
52.8
vs History
14
vs Industry
11
Median 3Y
40.4
Median 5Y
38.9
Industry
22.6
More Details
5.9
P/B
P/B
Price to Book Value
5.9
vs History
52
vs Industry
11
Median 3Y
5.4
Median 5Y
6.2
Industry
2
More Details
43.9
EV/S
EV/S
Enterprise Value to Sales
43.9
vs History
76
vs Industry
6
Median 3Y
46.8
Median 5Y
48.9
Industry
2.5
Forward
0.4
More Details
53.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
53.2
vs History
87
vs Industry
4
Median 3Y
59.1
Median 5Y
60.6
Industry
5
More Details
140.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
140.5
vs History
84
vs Industry
2
Median 3Y
153.2
Median 5Y
155.4
Industry
13.2
Forward
1.1
More Details
225.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
225.4
vs History
87
vs Industry
1
Median 3Y
274
Median 5Y
286.8
Industry
16.5
Forward
1.3
More Details
194.3
EV/OCF
EV/OCF
Enterprise Value to OCF
194.3
vs History
82
vs Industry
1
Median 3Y
214.5
Median 5Y
290.1
Industry
15.5
More Details
306
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
306
vs History
73
vs Industry
2
Median 3Y
332.8
Median 5Y
497.4
Industry
17.2
More Details
27.6
EV/IC
EV/IC
Enterprise Value to IC
27.6
vs History
73
vs Industry
4
Median 3Y
29.5
Median 5Y
29.8
Industry
1.9
More Details

Multiples Across Competitors

AZN Competitors Multiples
AstraZeneca PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
AstraZeneca PLC
LSE:AZN
186.4B GBP 5.1 39 140.5 225.4
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
688.2B USD 20.2 131.3 59.4 68.1
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK 16.6 46.2 33.8 36.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
JP
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
82T JPY 255.8 9 733.7 1 771.8 4 320.3
US
Johnson & Johnson
NYSE:JNJ
353.4B USD 4.3 8.7 11.6 15.3
US
Merck & Co Inc
NYSE:MRK
330.9B USD 5.5 906.7 45 87.9
CH
Novartis AG
SIX:NOVN
184B CHF 4.3 13.6 9.9 16.4
CH
Roche Holding AG
SIX:ROG
174.4B CHF 3 15.2 8.4 9.9
US
Pfizer Inc
NYSE:PFE
142.6B USD 2.4 67.3 10.3 15.2

See Also

Summary
AZN intrinsic value, competitors valuation, and company profile.
DCF Valuation
AZN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AZN stock valuation using valuation multiples.
Wall Street Estimates
AZN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AZN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 131,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.